Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Inclusion Criteria:

* Recurrent, metastatic or progressive NSCLC without any indication of radiotherapy. Subjects must have:
* Pathologically confirmed NSCLC
* Previously received treatment with single agent Gefitinib or Erlotinib and completed treatment at least 2 weeks prior to study entry
* Any one of the following:
* A tumor that harbors an EGFR mutation
* Objective clinical benefit from treatment with Gefitinib or Erlotinib as defined by either documented and confirmed partial or complete response (RECIST or WHO), or significant and durable (≥ 6 months) clinical benefit (stable disease as defined by RECIST or WHO) Progression of NSCLC while on continuous treatment with gefitinib or erlotinib as noted by CT/MRI increase in disease after having a confirmed partial or complete response or evidence of ≥ 6 months of SD within 3 months of study enrollment

Exclusion Criteria:

* Symptomatic brain metastasis
* History of TIA, CVA, or thrombotic/thromboembolic event (within last 6 months)
* History of hemoptysis greater than 10 mL/day within last 30 days
* Uncontrolled or significant cardiovascular disease
* History of uncontrolled diarrhea, Crohn's disease or ulcerative colitis
* Inability to swallow tablets, untreated malabsorption or GI surgery that results in inability to absorb protocol therapy
* Women unwilling to avoid pregnancy or use adequate contraception
* History of allergy or adverse drug reaction to gefitinib or erlotinib